The present disclosure relates to a composition for ameliorating a circulatory system disease, which contains a green tea extract with modified ingredient content. According to the present disclosure, it is possible to effectively prevent, ameliorate and treat circulatory system diseases without side effects and, thereby, to greatly help patients with circulatory system diseases and contribute to the development of related industries.

The present disclosure relates to a composition for ameliorating a circulatory system disease, which contains a green tea extract with modified ingredient content. According to the present disclosure, it is possible to effectively prevent, ameliorate and treat circulatory system diseases without side effects and, thereby, to greatly help patients with circulatory system diseases and contribute to the development of related industries.

Suggested is a cooling preparation comprising phenylalkenals and homovanillic acid esters.

Suggested is a cooling preparation comprising phenylalkenals and homovanillic acid esters.

Low cariogenic and low-laxation chewy confections comprising a non-cariogenic sweetener comprising erythritol and a doctoring agent comprising at least one of sucromalt, linear inulin, branched inulin, brown rice syrup, indigestible dextrin, polydextrose, isomaltooligosaccharide, and soluble corn fiber are provided. Methods for preparing low cariogenic and low-laxation chewy confections are also provided.

Low cariogenic and low-laxation chewy confections comprising a non-cariogenic sweetener comprising erythritol and a doctoring agent comprising at least one of sucromalt, linear inulin, branched inulin, brown rice syrup, indigestible dextrin, polydextrose, isomaltooligosaccharide, and soluble corn fiber are provided. Methods for preparing low cariogenic and low-laxation chewy confections are also provided.

Provided are non-dairy yogurt analogs that have qualities similar to those of dairy-based yogurts. Certain embodiments are to plant-based yogurt analogs comprising fermented plant protein isolates and/or gelled plant protein isolates. Also provided are processes for production of such non-dairy yogurt analogs. For instance, a method for producing a plant-based yogurt mixture capable of being used to make a plant-based yogurt analog comprising the steps of: a) obtaining an essentially dairy-free base for a yogurt formulation that includes a plant-based derivative, such as a paste; and b) adding an acid to said formulation. Thereafter, the plant-based yogurt formulation may be used to manufacture a plant-based yogurt analog comprising the steps of: a) heating a plant-based yogurt mixture at for a first pre-determined amount of time while stirring; b) allowing the mixture to cool; c) adding yogurt cultures to the resultant mixture; and d) incubating the resultant mixture for a second pre-determined amount of time to produce a plant-based yogurt analog.

Provided are non-dairy yogurt analogs that have qualities similar to those of dairy-based yogurts. Certain embodiments are to plant-based yogurt analogs comprising fermented plant protein isolates and/or gelled plant protein isolates. Also provided are processes for production of such non-dairy yogurt analogs. For instance, a method for producing a plant-based yogurt mixture capable of being used to make a plant-based yogurt analog comprising the steps of: a) obtaining an essentially dairy-free base for a yogurt formulation that includes a plant-based derivative, such as a paste; and b) adding an acid to said formulation. Thereafter, the plant-based yogurt formulation may be used to manufacture a plant-based yogurt analog comprising the steps of: a) heating a plant-based yogurt mixture at for a first pre-determined amount of time while stirring; b) allowing the mixture to cool; c) adding yogurt cultures to the resultant mixture; and d) incubating the resultant mixture for a second pre-determined amount of time to produce a plant-based yogurt analog.

Choline alfoscerate is a drug used to improve cerebrovascular diseases and brain metabolism. It is a drug with proven safety, which has no effect on the kidney and liver and with no severe side effect reported. When administered to a patient with muscle cramps, it can significantly reduce pain and the occurrence of muscle cramps. Accordingly, it may be used as an active ingredient in a pharmaceutical composition for treating or preventing muscle cramps and a health functional food composition for improving muscle cramps and may also be used for a method for treating muscle cramps by administering choline alfoscerate. In addition, choline alfoscerate may also be used to prepare a medication for treating muscle cramps.

Choline alfoscerate is a drug used to improve cerebrovascular diseases and brain metabolism. It is a drug with proven safety, which has no effect on the kidney and liver and with no severe side effect reported. When administered to a patient with muscle cramps, it can significantly reduce pain and the occurrence of muscle cramps. Accordingly, it may be used as an active ingredient in a pharmaceutical composition for treating or preventing muscle cramps and a health functional food composition for improving muscle cramps and may also be used for a method for treating muscle cramps by administering choline alfoscerate. In addition, choline alfoscerate may also be used to prepare a medication for treating muscle cramps.